A Phase 1/2 clinical trial Opdivo (nivolumab) and NKTR-214 combination in melanoma, kidney, colorectal, bladder and non-small cell lung cancer patients.

Trial Profile

A Phase 1/2 clinical trial Opdivo (nivolumab) and NKTR-214 combination in melanoma, kidney, colorectal, bladder and non-small cell lung cancer patients.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Nivolumab (Primary) ; NKTR 214 (Primary)
  • Indications Bladder cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top